0HFR Stock Overview
A clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Anavex Life Sciences Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.40 |
| 52 Week High | US$10.49 |
| 52 Week Low | US$3.30 |
| Beta | 0.60 |
| 11 Month Change | 68.52% |
| 3 Month Change | 52.65% |
| 1 Year Change | 32.82% |
| 33 Year Change | -50.40% |
| 5 Year Change | n/a |
| Change since IPO | 211.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HFR | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 14.1% | 1.5% | 1.7% |
| 1Y | 32.8% | -16.3% | 8.4% |
Return vs Industry: 0HFR exceeded the UK Biotechs industry which returned -16.3% over the past year.
Return vs Market: 0HFR exceeded the UK Market which returned 8.4% over the past year.
Price Volatility
| 0HFR volatility | |
|---|---|
| 0HFR Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0HFR's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0HFR's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 40 | Chris Missling | www.anavex.com |
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer’s disease and Parkinson’s disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company’s drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer’s disease.
Anavex Life Sciences Corp. Fundamentals Summary
| 0HFR fundamental statistics | |
|---|---|
| Market cap | US$766.13m |
| Earnings (TTM) | -US$41.53m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-18.4x
P/E RatioIs 0HFR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HFR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$41.53m |
| Earnings | -US$41.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.49 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0HFR perform over the long term?
See historical performance and comparison